Review, Early Access,
Personalised therapy in follicular lymphoma - is the dial turning?
Contributors
Specht, L.
0000-0002-6902-2190
[3]
[4]
Kimby, Eva
0000-0003-3078-6131
[8]
de Jong, Daphne
0000-0002-9725-4060
[9]
Cottereau de Segovia, Anne Segolene
0000-0002-4805-4564
[12]
[13]
[14]
sarkozy, clementine
0000-0002-1942-9304
[16]
[17]
[18]
Okosun, Jessica
0000-0001-6021-5044
[19]
[20]
Affiliations
- [1] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, England [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [2] Univ Manchester, Div Canc Sci, 555 Wilmslow Rd, Manchester M20 4GJ, England [NORA names: United Kingdom; Europe, Non-EU; OECD];
- [3] Copenhagen Univ Hosp Rigshosp, Dept Oncol, Copenhagen, Denmark [NORA names: Capital Region of Denmark; Hospital; Denmark; Europe, EU; Nordic; OECD];
- [4] Copenhagen Univ Hosp Rigshosp, Dept Oncol, Copenhagen, Denmark [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD];
- [5] Ctr Helmatol Pavlovsky, Buenos Aires, Argentina [NORA names: Argentina; America, South];
(... more)
Abstract
Follicular lymphoma is the most common indolent lymphoma accounting for approximately 20%-25% of all new non-Hodgkin lymphoma diagnoses in western countries. Whilst outcomes are mostly favorable, the spectrum of clinical phenotypes includes high-risk groups with significantly inferior outcomes. This review discusses recent updates in risk stratification and treatment approaches from upfront treatment for limited and advanced stage follicular lymphoma to the growing options for relapsed, refractory disease with perspectives on how to approach this from a personalized lens. Notable gaps remain on how one can precisely and prospectively select optimal treatment for patients based on varying risks, with an anticipation that an increased understanding of the biology of these different phenotypes and increasing refinement of imaging- and biomarker-based tools will, in time, allow these gaps to be closed.
